Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Programmed cell death ligand 2 (PD-L2)
- Target
- PD-L2
- Molecular classification
- Type I transmembrane protein, B7 protein family, Immune checkpoint receptor ligand
01
Overview
Programmed cell death ligand 2 (PD-L2) is a type I transmembrane protein and a member of the B7 protein family. It acts as a negative regulator of T cell activity by binding to its receptor, programmed cell death protein 1 (PD-1), inhibiting T-cell proliferation and cytokine production. PD-L2 plays a crucial role in maintaining immune tolerance and preventing autoimmunity. It is expressed on antigen-presenting cells and some T cells. In the context of cancer, PD-L2 expression on tumor cells or within the tumor microenvironment can contribute to immune evasion. Therapeutic antibodies targeting the PD-1/PD-L1/PD-L2 pathway are used in cancer immunotherapy.
- Other names
- PDCD1LG2B7-DCCD273
02
Mechanism of action
Blocks the interaction between PD-L2 and PD-1, preventing T cell inhibition.
03
Biological functions
Negative regulation of T cell activityInhibition of T-cell proliferationInhibition of IL-2 productionInhibition of IFN-gamma productionMaintenance of immune toleranceDownregulation of adaptive immune responses
04
Disease associations
CancerAutoimmunityImmune evasion
05
Safety considerations
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors
06
Interacting drugs
Anti-PD-(L)1 antibodies
07
Biomarkers
PD-L2 expression level in tumor cellsPD-L1 expression level in tumor cellsCo-expression of PD-L1 and PD-L2
Beyond the preview
Go deeper on Programmed cell death ligand 2 (PD-L2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Programmed cell death ligand 2 (PD-L2).